The Effect of Danshen on Fibrosis and Iron Metabolism in a Rat Model of Hepatic Fibrosis
International Journal of Pharmacology · 24.04.2026 · 22 (2)
DOI: 10.31083/ijp46622 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmacology, online erschienen am 24.04.2026. Verfasst von Wuying Ou und 1 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hainan Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Hepatic fibrosis (HF) is a major global health burden with limited effective therapies. Ferroptosis, an iron-dependent form of cell death, and inflammatory pathways are implicated in HF progression. Salvia miltiorrhiza (Danshen) has demonstrated antifibrotic effects, but its underlying mechanisms remain unclear.
Objective
To elucidate the mechanisms of Danshen in treating HF through network pharmacology and experimental validation, focusing on the JAK/STAT pathway, iron metabolism, and ferroptosis.
Methods
Using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, we identified 92 common targets among Danshen components, HF-related genes, and iron metabolism genes. A CCl4-induced HF rat model was established (n = 70) and treated with Danshen (3 or 6 g/kg/d) for 4 weeks. Hepatic fibrosis was assessed by Masson staining. Serum markers including Fe2+, transferrin (TRF), ferritin (SF), type III procollagen (PCIII), hydroxyproline (HyP), malondialdehyde (MDA), and glutathione (GSH) were measured. Western blotting evaluated hepatic expression of IL-6, P-JAK2, p-STAT3, and GPX4.
Results
Network pharmacology revealed JAK2/STAT3 as top hub genes among 92 intersection targets. High-dose Danshen decreased IL-6, P-JAK2, and p-STAT3 expression by 45–60% (p < 0.05), increased serum Fe2+ and TRF by 1.8-fold, and reduced SF, HyP by >40% and PCIII by >15% (p < 0.05). Additionally, Danshen restored GPX4 protein expression and suppressed ferroptosis by decreasing MDA while increasing GSH (p < 0.01). Masson staining showed 55% reduction in collagen deposition with high-dose treatment.
Conclusion
Danshen alleviates hepatic fibrosis by modulating the JAK/STAT-iron-ferroptosis axis, establishing a novel multi-target therapeutic strategy for HF.
Förderung
- Hainan Provincial Natural Science Foundation of China
Zitieren
APA
Ou, W., & Li, C. (2026). The Effect of Danshen on Fibrosis and Iron Metabolism in a Rat Model of Hepatic Fibrosis. International Journal of Pharmacology, 22(2). https://doi.org/10.31083/ijp46622
Vancouver
Ou W, Li C. The Effect of Danshen on Fibrosis and Iron Metabolism in a Rat Model of Hepatic Fibrosis. International Journal of Pharmacology. 2026;22(2). doi:10.31083/ijp46622
BibTeX
@article{Ou2026,
author = {Ou, Wuying and Li, Chunyun},
title = {The Effect of Danshen on Fibrosis and Iron Metabolism in a Rat Model of Hepatic Fibrosis},
journal = {International Journal of Pharmacology},
year = {2026},
volume = {22},
number = {2},
doi = {10.31083/ijp46622}
}
EUVIMED